GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

NTRB · Jul 31, 2024

NutriBand Inc.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001213900-24-075159General Corporate
Revenue growth12thOwn-history percentile · N=17
Evidence method

Yoy · gp.fundamentals.revenue

-32.49% · CORE · VALID

Inventory pressure100thOwn-history percentile · N=16
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

50.55% · OPTIONAL · VALID

Gross marginRAWCurrent state valid · history insufficient
Evidence method

Level · gp.fundamentals.gross_margin

22.93% · CORE · NOT_ENOUGH_HISTORY

Operating margin35thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

-318.35% · CORE · VALID

R&D intensity88thOwn-history percentile · N=8
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

174.78% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History27 statesSelf-history eligible
Period transition

What moved in the state?

Growth Decreased
Previous
-14.34%
Current
-32.49%
Delta
-18.15%
Inventory Pressure Increased
Previous
41.25%
Current
50.55%
Delta
9.31%
Profitability Increased
Previous
-462.50%
Current
-318.35%
Delta
144.16%
R And D Intensity Decreased
Previous
238.55%
Current
174.78%
Delta
-63.77%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.